Atea Pharmaceuticals, Inc. AVIR
3.91 USD -0.05 (-1.26%)
As ofNov 18, 2026, 11:32 AM EST
3.87 Day range 4.00
2.93 52-week range 6.45
- YTD
- +9.52%
- 1 year
- +28.20%
News
benzinga.com Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $8 Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $7 to $8.
seekingalpha.com Atea Pharmaceuticals: A Clean DDI Profile And Shorter Treatment Duration Threaten Current Market Leaders Atea Pharmaceuticals is a Buy: positive Phase 3 HCV data and a runway into mid-2028 support a steep discount to estimated value. BEM/RZR achieved a 94% cure rate versus Epclusa's 95%, with an…benzinga.com CORRECTION: Atea Pharmaceuticals Q3 EPS $(0.40) Beats $(0.42) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 4.76 percent. This is a 24.53 percent increase over losses of…
benzinga.com Atea Pharmaceuticals Q3 2026 Earnings Call Transcript Atea Pharmaceuticals (NASDAQ:AVIR) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Atea Pharmaceuticals Q3 EPS $0.40 Beats $(0.42) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $(0.42) by 195.24 percent. This is a 175.47 percent increase over losses…
